Pharmaceutical Economics


Edgeworth’s experts have deep experience analyzing economic issues in the pharmaceutical industry in the areas of antitrust, intellectual property, commercial damages, and consumer protection. Since our founding in 2009, Edgeworth’s economists have served as both testifying and consulting economists on a wide array of industry-specific matters before courts and regulatory authorities.

Our pharmaceutical economics experts have assisted clients across the industry, including brand and generic pharmaceutical companies, biotechnology companies, product manufacturers, healthcare providers, and insurers. We have performed analysis and testified in a variety of cases on issues including class certification, antitrust liability, antitrust damages, patent infringement, and product liability.  In these contexts, Edgeworth experts have assessed economic and econometric issues in the pharmaceutical industry relating to:

  • Pay for Delay
  • Product Hopping
  • Price Fixing
  • Bid Rigging
  • Exclusive Contracting
  • Consumer Protection
  • False Advertising
  • Intellectual Property Damages
  • Valuation
  • Contract Disputes

Case Highlights

Insights & News


  • Published Article, Bloomberg Law | 07.11.2024

    Edgeworth experts Dr. George Korenko and Dr. Tram Nguyen describe FTC actions and recent court decisions and how they affect the recent state of economic analysis of antitrust impact for these alleged patent practices in the pharmaceutical industry.

  • Published Article, Law360 | 05.16.2022

    In this article, Dr. George Korenko and Dr. Tram Nguyen identify dimensions along which, over aggregation and averaging, likely lead to findings of uninjured class members.

  • Published Article, Law360 | 07.21.2020

    In this article, published in Law360, Edgeworth Partner Dr. George Korenko and Principal Consultant Dr. Tram Nguyen discuss three key issues cited in the Court of Appeals opinion and their implications for the economic analysis of predominance in the Lamictal case and in other pay-for-delay litigations.

Edgeworth Insights

  • Blog, 09.06.2022

    When pharmaceutical manufacturers develop a new branded drug to take to market, they are granted a period of exclusivity via patent to help recoup the massive costs of research and development. Upon expiration of this patent, generic manufacturers can enter the market with therapeutically equivalent products and compete with the brand.

Speaking Engagements


The Antitrust Prescription

The Antitrust Prescription

Project Experience

Project Experience

Edgeworth has worked on numerous matters involving the economics of the pharmaceutical industry and drug pricing for both direct and indirect purchasers, including matters involving allegations of delayed generic entry, reverse payments, product-hopping, or other exclusionary practices.  Representative matters include:

  • In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
  • In Re: Opana ER Antitrust Litigation
  • In Re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation
  • In Re: Nexium (Esomeprazole) Antitrust Litigation
  • In Re: Wellbutrin XL Antitrust Litigation

Practice Contacts


Jump to Page

This website uses cookies to improve functionality and performance. By continuing to use this website, you agree to the use of cookies in accordance with our Privacy Policy.  If you are a California resident, read our California Information Practices.